Scarica l'app Stockscreener
17.57
0.29%
0.05
Dopo l'orario di chiusura:
17.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$17.52
Aprire:
$17.73
Volume 24 ore:
2.14M
Relative Volume:
0.99
Capitalizzazione di mercato:
$2.92B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
97.61
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
+1.80%
1M Prestazione:
+0.92%
6M Prestazione:
-4.25%
1 anno Prestazione:
-37.21%
Intervallo 1D:
$17.35
$17.89
Intervallo di 1 settimana:
$16.61
$18.23
Portata 52W:
$14.15
$29.29
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
17.57 | 2.92B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 6.9%Time to Sell? - MarketBeat
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
JPM25: After taking the wheel at Acadia, CEO Catherine Owen Adams looks to steer firm toward $1B in sales - FiercePharma
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised) - MSN
Burney Co. Purchases New Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Neuren partner submits Rett drug for EU approval - NT News
Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025 - GuruFocus.com
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 6.9%Time to Sell? - MarketBeat
Acadia expects more than $1B in sales for 2025 - MSN
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome - Agenzia ANSA
Acadia seeks EMA nod for first Rett syndrome therapy - Investing.com India
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference - The Bakersfield Californian
Acadia Pharma Targets $1B Sales Milestone in 2025, Expands DAYBUE to European Market - StockTitan
Acadia Pharma (ACAD) Submits Marketing Authorization Application to the EMA for Trofinetide for the Treatment of Rett Syndrome - StreetInsider.com
Acadia Seeks EU Approval for Breakthrough Rett Syndrome Drug Trofinetide After Phase 3 Success - StockTitan
(ACAD) Proactive Strategies - Stock Traders Daily
Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61% - Yahoo Finance
Why Investors Shouldn't Be Surprised By ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Low P/S - Simply Wall St
Acadia Pharmaceuticals downgraded to Neutral from Buy at Guggenheim - MSN
Principal Financial Group Inc. Increases Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World
ACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded to “Neutral” Rating by Guggenheim - Defense World
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap DownHere's What Happened - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded to Neutral Rating by Guggenheim - MarketBeat
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues - MSN
ACADIA Pharmaceuticals Inc.(NasdaqGS: ACAD) added to S&P 600 Health Care - Marketscreener.com
(ACAD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ACADIA Pharmaceuticals (NASDAQ:ACAD) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing - Insider Monkey
Acadia Pharma (ACAD) 5400 contracts of February 19 calls trade - StreetInsider.com
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide - Benzinga
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet - Benzinga
Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday - Benzinga
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap UpHere's What Happened - MarketBeat
Acadia Pharmaceuticals Shares Rise With Co to Join S&P SmallCap 600 - MarketWatch
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance
Short Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreases By 5.5% - Defense World
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Decrease in Short Interest - MarketBeat
Acadia Pharma (ACAD) to Join S&P SmallCap 600 - StreetInsider.com
Acadia Pharmaceuticals Set to Join S&P SmallCap 600 - Yahoo Finance
3 Specialty Pharma Stocks Addressing Unmet Medical Needs - Inkl
NBIX: 3 Specialty Pharma Stocks Addressing Unmet Medical Needs - StockNews.com
Acadia presents preclinical characterization of ACP-204 - BioWorld Online
Geode Capital Management LLC Has $44.23 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):